PMID- 19010854
OWN - NLM
STAT- MEDLINE
DCOM- 20090105
LR  - 20151119
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 14
IP  - 22
DP  - 2008 Nov 15
TI  - Predictive value of plasma hepatocyte growth factor/scatter factor levels in 
      patients with clinically localized prostate cancer.
PG  - 7385-90
LID - 10.1158/1078-0432.CCR-07-5110 [doi]
AB  - PURPOSE: Hepatocyte growth factor/scatter factor (HGF/SF) is a multifunctional 
      cytokine that is involved in cancer growth, motility, invasion, and angiogenesis. 
      We assessed whether preoperative plasma levels of HGF can enhance the accuracy of 
      standard models for predicting pathologic features and clinical outcomes. 
      EXPERIMENTAL DESIGN: The study comprised 421 consecutive patients treated with 
      radical prostatectomy and bilateral lymphadenectomy for clinically localized 
      prostatic adenocarcinoma. HGF/SF was measured using a commercially available 
      immunoassay. Multivariate logistic regression was used to assess the relationship 
      between plasma HGF/SF and pathologic features. Multivariate Cox regression was 
      used to predict disease recurrence. One thousand bootstrap replicates were 
      created for internal validation and predictive accuracies were estimated for each 
      model. RESULTS: Plasma HGF/SF levels were significantly elevated in patients with 
      lymph node and/or seminal vesicle invasion (P < 0.0001 and P = 0.007, 
      respectively). Preoperative plasma HGF/SF level was an independent predictor of 
      lymph node invasion [odds ratio (OR) for every 100 pg/mL increase in HGF/SF, 
      1.82; 95% confidence interval (95% CI), 1.33-2.49] and seminal vesicle invasion 
      (OR, 1.18; 95% CI, 1.06-1.3). Addition of HGF/SF increased the accuracy of a base 
      model that included standard preoperative variables for prediction of lymph node 
      invasion by 6.7% (predictive accuracy, 98.4%). HGF/SF also independently 
      predicted disease recurrence after surgery (hazard ratio, 1.07; 95% CI, 
      1.0-1.15). CONCLUSIONS: Preoperative plasma level of HGF/SF is an independent 
      predictor of prostate cancer metastasis to lymph nodes and disease recurrence 
      after surgery. Use of HGF may help in therapeutic decision-making and enrollment 
      into clinical trials.
FAU - Gupta, Amit
AU  - Gupta A
AD  - Department of Urology, The University of Texas Southwestern Medical Center, 
      Dallas, Texas 75390-9110, USA.
FAU - Karakiewicz, Pierre I
AU  - Karakiewicz PI
FAU - Roehrborn, Claus G
AU  - Roehrborn CG
FAU - Lotan, Yair
AU  - Lotan Y
FAU - Zlotta, Alexandre R
AU  - Zlotta AR
FAU - Shariat, Shahrokh F
AU  - Shariat SF
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Biomarkers, Tumor)
RN  - 67256-21-7 (Hepatocyte Growth Factor)
SB  - IM
MH  - Adenocarcinoma/*blood/*pathology/surgery
MH  - Biomarkers, Tumor/*blood
MH  - Hepatocyte Growth Factor/*blood
MH  - Humans
MH  - Immunoassay
MH  - Lymph Node Excision
MH  - Lymphatic Metastasis/pathology
MH  - Male
MH  - Neoplasm Recurrence, Local/blood/pathology
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Prostatectomy
MH  - Prostatic Neoplasms/*blood/*pathology/surgery
EDAT- 2008/11/18 09:00
MHDA- 2009/01/06 09:00
CRDT- 2008/11/18 09:00
PHST- 2008/11/18 09:00 [pubmed]
PHST- 2009/01/06 09:00 [medline]
PHST- 2008/11/18 09:00 [entrez]
AID - 14/22/7385 [pii]
AID - 10.1158/1078-0432.CCR-07-5110 [doi]
PST - ppublish
SO  - Clin Cancer Res. 2008 Nov 15;14(22):7385-90. doi: 10.1158/1078-0432.CCR-07-5110.